Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
X Thomas, QH Le, S de Botton, E Raffoux, Y Chelghoum, C Pautas, F Dreyfus, N Dhedin, A Vekhoff, J Troncy, A Pigneux, T de Revel, O Reman, P Travade, A Thiebaut, A Guerci, M Elhamri, P Fenaux, H Dombret & M Michallet. (2005) Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy. Leukemia & Lymphoma 46:7, pages 1007-1016.
Read now
Read now
Articles from other publishers (13)
Vincenza Barresi, Virginia Di Bella, Nellina Andriano, Anna Provvidenza Privitera, Paola Bonaccorso, Manuela La Rosa, Valeria Iachelli, Giorgia Spampinato, Giulio Pulvirenti, Chiara Scuderi, Daniele F. Condorelli & Luca Lo Nigro. (2021) NUP-98 Rearrangements Led to the Identification of Candidate Biomarkers for Primary Induction Failure in Pediatric Acute Myeloid Leukemia. International Journal of Molecular Sciences 22:9, pages 4575.
Crossref
Crossref
Yi Xiao, Taoran Deng, Changliang Su & Zhen Shang. (2017) MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS. Oncology Letters 13:6, pages 4986-4994.
Crossref
Crossref
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu & Xiao-Jun Huang. (2016) Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy. Biology of Blood and Marrow Transplantation 22:12, pages 2235-2242.
Crossref
Crossref
N Daver, H Kantarjian, F Ravandi, E Estey, X Wang, G Garcia-Manero, E Jabbour, M Konopleva, S O'Brien, S Verstovsek, T Kadia, C Dinardo, S Pierce, X Huang, N Pemmaraju, M Diaz-Pines-Mateo, J Cortes & G Borthakur. (2015) A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 30:2, pages 268-273.
Crossref
Crossref
Paola Quarello, Franca Fagioli, Giuseppe Basso, Maria C. Putti, Massimo Berger, Matteo Luciani, Carmelo Rizzari, Giuseppe Menna, Riccardo Masetti & Franco Locatelli. (2015) Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial. British Journal of Haematology 171:4, pages 566-573.
Crossref
Crossref
Elias Jabbour, Naval Daver, Richard Champlin, Michael Mathisen, Betul Oran, Stefan Ciurea, Issa Khouri, A Megan Cornelison, Hady Ghanem, Marylou Cardenas- Turanzas, Uday Popat, Farhad Ravandi, Sergio Giralt, Guillermo Garcia-Manero, Jorge Cortes, Hagop Kantarjian & Marcos de Lima. (2014) Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. American Journal of Hematology 89:4, pages 395-398.
Crossref
Crossref
Ki-Seong Eom, Woo-Sung Min, Hee-Je Kim, Byung-Sik Cho, Su-Mi Choi, Dong-Gun Lee, Seok Lee, Chang-Ki Min, Yoo-Jin Kim, Seok-Goo Cho, Jong-Wook Lee & Chun-Choo Kim. (2010) FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia. Medical Oncology 28:S1, pages 462-470.
Crossref
Crossref
Betul Oran, Michelle Dolan, Qing Cao, Claudio Brunstein, Erica Warlick & Daniel Weisdorf. (2011) Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation 17:3, pages 356-364.
Crossref
Crossref
Je-Hwan LeeSung-Soo YoonChul Won JungJung-Hee LeeDae-Young KimYoung-Shin LeeSung Cheol YunInho KimSeonyang ParkByoung Kook KimKihyun KimJin Seok AhnKyoo-Hyung Lee. (2010) Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission. The Korean Journal of Hematology 45:2, pages 95.
Crossref
Crossref
Sung-Sook Lee, Je-Hwan Lee, Jung-Hee Lee, Dae-Young Kim, Se Hyung Kim, Sung-nam Lim, Young-Shin Lee, Miee Seol, Seong-Gil Ryu, Young-Ah Kang, Seongsoo Jang, Chan-Jeoung Park, Hyun-Sook Chi, Sung-Cheol Yun & Kyoo-Hyung Lee. (2009) Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia. Leukemia Research 33:4, pages 511-517.
Crossref
Crossref
Hien K. Duong & Matt Kalaycio. (2009) The role of gemtuzumab ozogamicin in combination chemotherapy regimens for primary resistant or relapsed acute myeloid leukemia. Current Hematologic Malignancy Reports 4:2, pages 55-56.
Crossref
Crossref
Anthony Calabro, Julia Tai, Steven L. Allen & Daniel R. Budman. (2008) In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. Anti-Cancer Drugs 19:7, pages 705-712.
Crossref
Crossref
Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Young-Shin Lee, Miee Seol, Seong-Gil Ryu, Seongsoo Jang, Chan-Jeoung Park, Hyun-Sook Chi, Jung-Shin Lee, Woo-Kun Kim & Kyoo-Hyung Lee. (2006) Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia. Leukemia Research 30:2, pages 204-210.
Crossref
Crossref